Trials / Withdrawn
WithdrawnNCT00447356
High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma
Phase III Randomized Study of Four Weeks High Dose IFN-2b in StageT3-T4 or N1 (Microscopic) Melanoma
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Hackensack Meridian Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Detailed description
Interferon alfa may interfere with growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant interferon alfa |
Timeline
- Start date
- 2000-01-01
- First posted
- 2007-03-14
- Last updated
- 2013-05-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00447356. Inclusion in this directory is not an endorsement.